Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome

Alberto Lleó (), Henrik Zetterberg, Jordi Pegueroles, Thomas K. Karikari, María Carmona-Iragui, Nicholas J. Ashton, Victor Montal, Isabel Barroeta, Juan Lantero-Rodríguez, Laura Videla, Miren Altuna, Bessy Benejam, Susana Fernandez, Silvia Valldeneu, Diana Garzón, Alexandre Bejanin, Maria Florencia Iulita, Valle Camacho, Santiago Medrano-Martorell, Olivia Belbin, Jordi Clarimon, Sylvain Lehmann, Daniel Alcolea, Rafael Blesa, Kaj Blennow and Juan Fortea ()
Additional contact information
Alberto Lleó: Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
Henrik Zetterberg: Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg
Jordi Pegueroles: Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
Thomas K. Karikari: Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg
María Carmona-Iragui: Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
Nicholas J. Ashton: Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg
Victor Montal: Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
Isabel Barroeta: Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
Juan Lantero-Rodríguez: Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg
Laura Videla: Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
Miren Altuna: Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
Bessy Benejam: Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
Susana Fernandez: Barcelona Down Medical Center, Fundació Catalana Síndrome de Down
Silvia Valldeneu: Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
Diana Garzón: Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
Alexandre Bejanin: Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
Maria Florencia Iulita: Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
Valle Camacho: Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
Santiago Medrano-Martorell: Hospital del Mar-Universitat Autònoma Barcelona (UAB)
Olivia Belbin: Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
Jordi Clarimon: Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
Sylvain Lehmann: The Institute for Neurosciences of Montpellier, Université de Montpellier, Centre Hospitalier Universitaire de Montpellier, INSERM
Daniel Alcolea: Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
Rafael Blesa: Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
Kaj Blennow: Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg
Juan Fortea: Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona

Nature Communications, 2021, vol. 12, issue 1, 1-8

Abstract: Abstract Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer’s disease (AD) pathology with high accuracy in the general population. In this study, we investigated plasma p-tau181 as a biomarker of AD in individuals with Down syndrome (DS). We included 366 adults with DS (240 asymptomatic, 43 prodromal AD, 83 AD dementia) and 44 euploid cognitively normal controls. We measured plasma p-tau181 with a Single molecule array (Simoa) assay. We examined the diagnostic performance of p-tau181 for the detection of AD and the relationship with other fluid and imaging biomarkers. Plasma p-tau181 concentration showed an area under the curve of 0.80 [95% CI 0.73–0.87] and 0.92 [95% CI 0.89–0.95] for the discrimination between asymptomatic individuals versus those in the prodromal and dementia groups, respectively. Plasma p-tau181 correlated with atrophy and hypometabolism in temporoparietal regions. Our findings indicate that plasma p-tau181 concentration can be useful to detect AD in DS.

Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-021-24319-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-24319-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-24319-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().